Financial Performance & Guidance - Q3 2025 revenue was $353 million, a decrease of $48 million compared to Q3 2024[39] - Adjusted EBITDA for Q3 2025 was $42 million, down $9 million from Q3 2024[39] - The company projects Q4 2025 Adjusted Free Cash Flow to be between $25 million and $30 million[39] - 2025 Adjusted EBITDA guidance is $135-140 million[39] Segment Performance - Cellulose Specialties Q3 2025 Adjusted EBITDA was $66 million with a 32% margin[39, 40] - Biomaterials Q3 2025 Adjusted EBITDA was $1 million with a 13% margin[39, 45] - Cellulose Commodities Q3 2025 Adjusted EBITDA was negative $3 million with a negative 4% margin[39, 48] - Paperboard Q3 2025 Adjusted EBITDA was $1 million with a 3% margin[39, 54] - High-Yield Pulp Q3 2025 Adjusted EBITDA was negative $9 million with a negative 38% margin[39, 60] Strategic Initiatives - The company aims to restore Temiscaming profitability with $10 million annual EBITDA improvement through cost reduction and $10 million annual EBITDA improvement by improving Paperboard Operational Equipment Efficiency (OEE)[20] - The company expects Biomaterials to contribute approximately $31 million of proportional run-rate EBITDA in 2027 and approximately $80 million including proportional AGE EBITDA in 2028[34]

Bank of America's Strategic Priorities - Bank of America aims to drive organic growth while managing risk and expenses to deliver industry-leading shareholder value through strong profitability and capital management[6, 64] - The company focuses on executing a customer and client-focused model leveraging industry-leading platforms across integrated world-class businesses[6] - Bank of America emphasizes technology leadership fueled by continuous investments in both high-tech and high-touch capabilities[6] Financial Performance and Targets - Bank of America's Consumer Banking segment reported $108 billion in net income in 2024 with a 25% return on average allocated capital[76] - The Global Wealth & Investment Management (GWIM) segment had $43 billion in net income in 2024 with a 23% return on average allocated capital[207] - The Global Banking segment's net income was $81 billion in 2024 with a 17% return on average allocated capital[320] - The Global Markets segment's net income was $56 billion in 2024 with a 12% return on average allocated capital[552] Growth and Innovation - Bank of America is investing over $100 billion in technology over the past decade, including $15 billion+ in data capabilities since 2021[43] - The company is expanding its footprint in growth markets, with plans for 6 additional markets through 2028[161] - Bank of America is leveraging AI to drive innovation and improve productivity, with investments in Erica and AI-enabled processes[43]

Q3 2025 Financial Performance - Net sales reached $178 million, reflecting 10% organic growth[18] - Adjusted EPS stood at $0.36[18] - Adjusted EBITDA amounted to $20 million with an 11% margin[18] Segment Performance - Specialty Nutrition Systems experienced 14.5% organic growth, with net sales of $114 million[20] - Specialty Nutrition Systems operating profit was $23 million, representing a 20% margin[21] - Pain Management & Recovery saw 2.4% organic growth, with net sales of $59 million[26] 2025 Outlook - Net sales are estimated to be between $690 million and $700 million[16, 33] - Adjusted EPS is projected to be between $0.85 and $0.95 per share[16, 33] Financial Position - Cash balance was $70 million as of September 30, 2025[31] - Net debt was $(33) million, with a net debt to EBITDA ratio of approximately 0.4x[31] Strategic Initiatives - Expanded transformation initiatives are expected to deliver $15 to $20 million of incremental annualized savings by the end of 2026[16]

Company Overview - IGI's total assets reached approximately $700 million as of full year 2024[4] - IGI's gross written premium was approximately $21 billion as of September 30, 2025[4] - IGI has an average 10-Year Core ROE of 140% and an average combined ratio of 870% from 2015-2024[4] - The Jabsheh family holds 358% ownership in IGI as of September 30, 2025[9] Financial Performance (Q3/9M 2025) - Net income for Q3 2025 was $335 million, a decrease of 29% compared to Q3 2024[20] - Net income for 9M 2025 was $949 million, a decrease of 97% compared to 9M 2024, primarily due to lower underwriting income[20] - The combined ratio for Q3 2025 was 765%, benefiting from a positive foreign currency revaluation of 46 points[20] - The combined ratio for 9M 2025 was 871%, negatively impacted by a foreign currency revaluation of 75 points[20] - Underwriting income for Q3 2025 was $514 million, a 242% increase compared to Q3 2024, influenced by lower losses and positive foreign currency revaluation of $50 million[20] - Underwriting income for 9M 2025 was $1143 million, a 176% decrease compared to 9M 2024, impacted by higher losses, reinstatement premiums, and negative foreign currency revaluation of $236 million[20] - Book value per share was $1623, a 57% increase from June 30, 2025, and a 93% increase from December 31, 2024[20] - Capital returned to shareholders in Q3 2025 amounted to $209 million through dividends and share repurchases (790k shares)[20] - Capital returned to shareholders in 9M 2025 totaled $979 million, including a $085 extraordinary dividend in Q1 and share repurchases (23m shares)[20] Investment Portfolio - The total investment portfolio was $1316 billion as of September 30, 2025[28] - The average credit quality of the investment portfolio is A, with a duration of 37 years[28] - The bond portfolio is geographically diversified, with 41% in North America, 11% in the UK, 18% in Europe, 15% in Australasia, and 14% in the Middle East[28]

Financial Performance - Hamilton's Gross Premiums Written (GPW) reached $2.4 billion in FY 2024 [12], and $2.3 billion for the first nine months of 2025 [12] - The company's underwriting income was $149 million in FY 2024 [12], but decreased to $73 million for the first nine months of 2025 [12] - Hamilton's combined ratio was 91.3% in FY 2024 [12], but increased to 95.2% for the first nine months of 2025 [12] - Net income was $400 million in FY 2024 [12], and $405 million for the first nine months of 2025 [12] - As of September 30, 2025, Hamilton had $5.7 billion in cash and invested assets [12], and $2.7 billion in shareholders' equity [12] Business Segments - In 2024, the International segment's GPW was $1.3 billion [29], with Hamilton Select contributing $117 million, or 9% [29] - The International segment's business mix in 2024 consisted of 43% Specialty, 42% Casualty, and 15% Property [29] - The Bermuda segment's GPW was $1.1 billion in 2024 [42] - The Bermuda segment's business mix in 2024 consisted of 47% Casualty, 38% Property, and 15% Specialty [42] Investment Strategy - As of September 30, 2025, Hamilton's investment portfolio totaled $5.7 billion [52] - 62.6% or $3.6 billion of the investment portfolio was allocated to Fixed Income, Short-Term and Cash [53] - 37.4% or $2.1 billion of the investment portfolio was allocated to the Two Sigma Hamilton Fund (TSHF) [53] - The fixed income portfolio, valued at $3.0 billion, had an average rating of Aa3 and a duration of 3.3 years [54]

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Supplemental Information contains forward-looking statements and information, within the meaning of Canadian securities laws and "forward-looking statements" within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, "safe harbor" provisions of the United States Private Securities Litigation Reform ...

Financial Performance & Outlook - 3Q 2025 net sales reached $2.618 billion, a 13% increase compared to 3Q 2024[33] - YTD 2025 net sales totaled $13.5 billion, a 4% increase year-over-year[21] - The company is raising its FY 2025 Operating EBITDA guidance to $3.80 - $3.90 billion, reflecting a 14% growth at the mid-point[18] - The company anticipates ~$1 billion in share repurchases for FY 2025[18] - Preliminary view for 2026 indicates a full-year Operating EBITDA of $4.1 billion at the mid-point[20] Segment Performance - Seed net sales in 3Q 2025 increased by 33% to $917 million, with organic sales growth of 31%[37] - Crop Protection net sales in 3Q 2025 increased by 4% to $1.701 billion, with organic sales growth of 3%[59] - YTD 2025 Seed net sales increased by 5% to $8.161 billion, with organic sales growth of 7%[49] - YTD 2025 Crop Protection net sales increased by 3% to $5.330 billion, with organic sales growth of 5%[71] Strategic Initiatives - The company is on track to separate into two market-leading public companies in 2H 2026[14] - Restructuring activities in the Crop Protection network are expected to result in approximately $160 million to $175 million net pre-tax restructuring charges during 2025[8]

Financial Performance Highlights - The company reported strong organic revenue growth of 5% in Q3 2025, driven by accelerating AMS/DRS growth[6] - AMS/DRS organic growth was 19% in Q3 2025, contributing to 28% of the total revenue mix[6] - Adjusted EBITDA margin reached a record 19% in Q3 2025, an increase of 180 basis points[6] - Free cash flow grew by 30% in Q3 2025, reaching $175 million[6] - The company utilized $154 million YTD to repurchase 17 million shares at $8905 per share[8] Growth Strategy and Outlook - The company is increasing its revenue mix expectation for AMS/DRS to 27-28%[13] - North America Adjusted EBITDA margins have expanded 370bps since 2022 and +190bps YTD[20] - The company's Q3 2025 revenue increased by 6% to $1335 million, with organic growth contributing 5%[23, 26] - Adjusted EBITDA increased by 17% to $253 million, with a margin of 19%[23] - The company projects full-year organic revenue growth of approximately 5% and Adjusted EBITDA margin expansion of 30-50 basis points[36]

Financial Performance - MannKind Corporation reported a record revenue quarter of $82 million[13] - Tyvaso DPI-related revenue reached $59 million in Q3 2025, a 15% increase from Q3 2024[13, 22] - Afrezza net revenue for Q3 2025 was $18.5 million, up 23% from Q3 2024[32] - FUROSCIX net revenue for Q3 2025 was $19.3 million, a 93% increase from Q3 2024[37] - Total revenue increased by 17% from Q3 2024 to Q3 2025[50] Product & Clinical Development - Afrezza sBLA was accepted for review, potentially becoming the first new insulin for pediatrics in over 100 years[13, 62] - FUROSCIX doses dispensed in Q3 2025 increased by 153% from Q3 2024[34] - The ICoN-1 global Phase 3 study achieved its interim enrollment target ahead of schedule[69] - INFLO Nintedanib DPI Phase 2 study was initiated, with the first patient expected to enroll in Q1 2026[15, 77] Market Opportunity - The addressable opportunity for heart failure (HF) is greater than $10 billion[39]

November 5, 2025 Disclaimer Sonida and CNL Healthcare Properties A Compelling Combination Important Information and Where to Find It • This presentation relates to a proposed transaction involving the Sonida Senior Living, Inc. ("Sonida") and CNL Healthcare Properties, Inc. ("CHP"). In connection with the proposed transaction, Sonida and CHP will each file relevant materials with the SEC, including a registration statement on Form S-4 to register the shares of Sonida common stock to be issued to the CHP sto ...